Literature DB >> 27060337

Role of hemostatic factors in hepatic injury and disease: animal models de-liver.

A K Kopec1,2, N Joshi3,2, J P Luyendyk1,3,2.   

Abstract

Chronic liver damage is associated with unique changes in the hemostatic system. Patients with liver disease often show a precariously rebalanced hemostatic system, which is easily tipped towards bleeding or thrombotic complications by otherwise benign stimuli. In addition, some clinical studies have shown that hemostatic system components contribute to the progression of liver disease. There is a strong basic science foundation for clinical studies with this particular focus. Chronic and acute liver disease can be modeled in rodents and large animals with a variety of approaches, which span chronic exposure to toxic xenobiotics, diet-induced obesity, and surgical intervention. These experimental approaches have now provided strong evidence that, in addition to perturbations in hemostasis caused by liver disease, elements of the hemostatic system have powerful effects on the progression of experimental liver toxicity and disease. In this review, we cover the basis of the animal models that are most often utilized to assess the impact of the hemostatic system on liver disease, and highlight the role that coagulation proteases and their targets play in experimental liver toxicity and disease, emphasizing key similarities and differences between models. The need to characterize hemostatic changes in existing animal models and to develop novel animal models recapitulating the coagulopathy of chronic liver disease is highlighted. Finally, we emphasize the continued need to translate knowledge derived from highly applicable animal models to improve our understanding of the reciprocal interaction between liver disease and the hemostatic system in patients.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  acute liver failure; animal models; coagulation; hemostasis; liver

Mesh:

Substances:

Year:  2016        PMID: 27060337      PMCID: PMC5091081          DOI: 10.1111/jth.13327

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  98 in total

1.  Parallel studies of complement and coagulation. IV. Effect of carbon tetrachloride.

Authors:  C E RICE; P BOULANGER; P J G PLUMMER
Journal:  Can J Med Sci       Date:  1951-04

2.  Platelets and protease-activated receptor-4 contribute to acetaminophen-induced liver injury in mice.

Authors:  Kazuhisa Miyakawa; Nikita Joshi; Bradley P Sullivan; Ryan Albee; Christina Brandenberger; Hartmut Jaeschke; Mitchell R McGill; Michael A Scott; Patricia E Ganey; James P Luyendyk; Robert A Roth
Journal:  Blood       Date:  2015-07-15       Impact factor: 22.113

3.  Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.

Authors:  A Phillip Owens; Freda H Passam; Silvio Antoniak; Stephanie M Marshall; Allison L McDaniel; Lawrence Rudel; Julie C Williams; Brian K Hubbard; Julie-Ann Dutton; Jianguo Wang; Peter S Tobias; Linda K Curtiss; Alan Daugherty; Daniel Kirchhofer; James P Luyendyk; Patrick M Moriarty; Shanmugam Nagarajan; Barbara C Furie; Bruce Furie; Douglas G Johns; Ryan E Temel; Nigel Mackman
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

4.  Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.

Authors:  Anna K Kopec; Nikita Joshi; Keara L Towery; Karen M Kassel; Bradley P Sullivan; Matthew J Flick; James P Luyendyk
Journal:  J Pharmacol Exp Ther       Date:  2014-08-19       Impact factor: 4.030

5.  Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat.

Authors:  Wataru Abe; Kenichi Ikejima; Tie Lang; Kyoko Okumura; Nobuyuki Enomoto; Tsuneo Kitamura; Yoshiyuki Takei; Nobuhiro Sato
Journal:  J Hepatol       Date:  2006-10-25       Impact factor: 25.083

6.  Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice.

Authors:  Sabine Oertelt; Zhe-Xiong Lian; Chun-Mei Cheng; Ya-Hui Chuang; Kerstien A Padgett; Xiao-Song He; William M Ridgway; Aftab A Ansari; Ross L Coppel; Ming O Li; Richard A Flavell; Mitchell Kronenberg; Ian R Mackay; M Eric Gershwin
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

7.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark
Journal:  Am J Epidemiol       Date:  2013-05-23       Impact factor: 4.897

8.  A reproducible, clinically relevant, intensively managed, pig model of acute liver failure for testing of therapies aimed to prolong survival.

Authors:  Karla C L Lee; Carolina Palacios Jimenez; Hatim Alibhai; Yu-Mei Chang; Pamela J Leckie; Luisa A Baker; Giacomo Stanzani; Simon L Priestnall; Rajeshwar P Mookerjee; Rajiv Jalan; Nathan A Davies
Journal:  Liver Int       Date:  2013-01-20       Impact factor: 5.828

9.  Effects of acute liver injury on blood coagulation.

Authors:  R Kerr; P Newsome; L Germain; E Thomson; P Dawson; D Stirling; C A Ludlam
Journal:  J Thromb Haemost       Date:  2003-04       Impact factor: 5.824

10.  Proteinase activated receptor 1 mediated fibrosis in a mouse model of liver injury: a role for bone marrow derived macrophages.

Authors:  Yiannis N Kallis; Christopher J Scotton; Alison C Mackinnon; Robert D Goldin; Nicholas A Wright; John P Iredale; Rachel C Chambers; Stuart J Forbes
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more
  8 in total

1.  Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis.

Authors:  Nikita Joshi; Anna K Kopec; Holly Cline-Fedewa; James P Luyendyk
Journal:  Toxicology       Date:  2016-12-31       Impact factor: 4.221

2.  Dose-dependent effects of alpha-naphthylisothiocyanate disconnect biliary fibrosis from hepatocellular necrosis.

Authors:  Nikita Joshi; Jessica L Ray; Anna K Kopec; James P Luyendyk
Journal:  J Biochem Mol Toxicol       Date:  2016-09-08       Impact factor: 3.642

3.  Inhibition of PAR-4 and P2Y12 receptor-mediated platelet activation produces distinct hepatic pathologies in experimental xenobiotic-induced cholestatic liver disease.

Authors:  Nikita Joshi; Anna K Kopec; Jessica L Ray; James P Luyendyk
Journal:  Toxicology       Date:  2016-07-27       Impact factor: 4.221

4.  Colonic hydrogen sulfide produces portal hypertension and systemic hypotension in rats.

Authors:  Tomasz Huc; Halina Jurkowska; Maria Wróbel; Kinga Jaworska; Maksymilian Onyszkiewicz; Marcin Ufnal
Journal:  Exp Biol Med (Maywood)       Date:  2017-11-13

Review 5.  The multifaceted role of fibrinogen in tissue injury and inflammation.

Authors:  James P Luyendyk; Jonathan G Schoenecker; Matthew J Flick
Journal:  Blood       Date:  2018-12-06       Impact factor: 22.113

Review 6.  Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?

Authors:  Dafna J Groeneveld; Lauren G Poole; James P Luyendyk
Journal:  J Thromb Haemost       Date:  2021-05-03       Impact factor: 16.036

Review 7.  Animal models applied to acute-on-chronic liver failure: Are new models required to understand the human condition?

Authors:  Jaciara Fernanda Gomes Gama; Liana Monteiro da Fonseca Cardoso; Jussara Machado Lagrota-Candido; Luiz Anastacio Alves
Journal:  World J Clin Cases       Date:  2022-03-26       Impact factor: 1.337

8.  Applications of the microphysiology systems database for experimental ADME-Tox and disease models.

Authors:  Mark Schurdak; Lawrence Vernetti; Luke Bergenthal; Quinn K Wolter; Tong Ying Shun; Sandra Karcher; D Lansing Taylor; Albert Gough
Journal:  Lab Chip       Date:  2020-04-14       Impact factor: 6.799

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.